Veeva Systems

VEEV

Market cap $27B

Despite the deregistration of Scion Asset Management in late 2025, the legendary ‘Big Short' trader, Michael Burry, has remained active in the stock market and has, in an April 13 update, revealed he had taken three new long positions.

Veeva (VEEV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

In the closing of the recent trading day, Veeva Systems (VEEV) stood at $151.43, denoting a -3.6% move from the preceding trading day.

Veeva Systems Inc. is upgraded to a Buy as valuation resets after a 30% YTD decline, despite continued strong fundamentals. VEEV's specialized, regulated software for life sciences makes it resilient to AI disruption and entrenched with major industry players. Revenue and billings growth remain in the mid-teens, with FY27 guidance targeting low-teens growth and mid-40s margins—approaching the Rule of 60.

VEEV expands RIM capabilities via RegASK AI partnership, adding real-time regulatory intelligence to boost compliance efficiency and decision-making.

Veeva (VEEV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

NEW YORK & SINGAPORE--(BUSINESS WIRE)--RegASK, the Agentic AI platform redefining regulatory intelligence and workflow orchestration, today announced its partnership with Veeva Systems, a leading provider of industry cloud solutions for the global life sciences industry. RegASK is joining the Veeva AI Partner Program to integrate with Veeva's Regulatory Information Management (RIM) system, enabling life sciences organizations to connect near-real-time regulatory signals with established complia.

Veeva Systems (VEEV) closed at $172.52 in the latest trading session, marking a -1.21% move from the prior day.

VEEV's strong Q4, expanding AI strategy and major life sciences partnerships fuel growth despite rising costs.

Veeva Systems is reiterated as a Buy, with the growth thesis now supported by traction across R&D, Quality, Commercial, and AI-driven solutions. R&D and Quality modules are gaining adoption among the top 20 biopharmas, broadening VEEV's customer base and cross-sell opportunities beyond core products. Vault CRM is driving stronger Commercial Solutions growth and acting as a catalyst for cross-selling adjacent products, increasing wallet share and customer stickiness.